For subcutaneous injections, the abdominal site is preferred for most peptides due to the consistent subcutaneous fat layer thickness, proximity to the gut-associated lymphoid tissue (relevant for some anti-inflammatory peptides), and the practical convenience of self-administration in research settings
However, this short window does not limit therapeutic benefit because BPC-157 triggers lasting biological changes rather than needing to remain constantly present
By isolating just this sequence, AOD-9604 is structurally distinct from full-length hGH it does not bind the same way to the growth hormone receptor, which is why studies have not shown it to raise IGF-1 levels the way full hGH or GHRH analogs like Tesamorelin do
For multiinjection doses, use different sites for each injection on the same day
None of the above peptides have gone through one
Transitioning between concentrations If your pharmacy changes your vial concentration (common when moving from initiation vials to maintenance vials), recalculate your syringe units immediately
